Cargando…

Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial

BACKGROUND: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. METHODS: In this double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Su Eun, Kim, Ok-Hwan, Kwak, Jung Hyun, Lee, Kwang-Hyoung, Kwon, Young-In, Chung, Kwang Hoe, Lee, Jong Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650494/
https://www.ncbi.nlm.nih.gov/pubmed/26578409
http://dx.doi.org/10.1186/s13063-015-1036-z
_version_ 1782401501202743296
author Park, Su Eun
Kim, Ok-Hwan
Kwak, Jung Hyun
Lee, Kwang-Hyoung
Kwon, Young-In
Chung, Kwang Hoe
Lee, Jong Ho
author_facet Park, Su Eun
Kim, Ok-Hwan
Kwak, Jung Hyun
Lee, Kwang-Hyoung
Kwon, Young-In
Chung, Kwang Hoe
Lee, Jong Ho
author_sort Park, Su Eun
collection PubMed
description BACKGROUND: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. METHODS: In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student’s t-test and paired t-test. RESULTS: After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (−19.4 ± 5.62 mg/dL) and 60 minutes (−15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (−27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose. CONCLUSIONS: Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus. TRIAL REGISTRATION: ClinicalTrials.gov NCT02285231. Registered 11 May 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-1036-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4650494
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46504942015-11-19 Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial Park, Su Eun Kim, Ok-Hwan Kwak, Jung Hyun Lee, Kwang-Hyoung Kwon, Young-In Chung, Kwang Hoe Lee, Jong Ho Trials Research BACKGROUND: A previous study reported that arginyl-fructose may have great value as a functional food with antioxidant and antidiabetic activities. However, there have been few clinical studies on the efficacy of arginyl-fructose supplementation for blood glucose control. METHODS: In this double-blind, placebo-controlled study, 60 Korean subjects with prediabetes or type 2 diabetes mellitus were randomly assigned to placebo or test groups. The test group subjects received 1500 mg/day arginyl-fructose. Fasting serum levels of glucose, hemoglobin A1c, insulin, and free fatty acids were measured by 2-hour oral glucose tolerance tests at baseline and after the 6-week intervention. Eleven subjects dropped out or were excluded during the trial. The data for the remaining 49 were statistically analyzed using Student’s t-test and paired t-test. RESULTS: After the 6-week intervention, the test group showed significant reductions in serum glucose levels at 30 minutes (−19.4 ± 5.62 mg/dL) and 60 minutes (−15.4 ± 7.01 mg/dL) and reduced glucose area under the curve (−27.4 ± 8.59 mg/dL) compared with those of the placebo control group. The changes (differences from baseline) in serum glucose levels at 60 minutes and glucose area under the curve in the test group differed significantly from those in the control group even after adjusting for baseline values. In contrast, glucose-related biomarkers including hemoglobin A1c, insulin, and C-peptide levels were not significantly improved by the dietary intervention with arginyl-fructose. CONCLUSIONS: Arginyl-fructose supplementation (1500 mg/day) may be beneficial for reducing postprandial blood glucose levels in patients with prediabetes or type 2 diabetes mellitus. TRIAL REGISTRATION: ClinicalTrials.gov NCT02285231. Registered 11 May 2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-1036-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-14 /pmc/articles/PMC4650494/ /pubmed/26578409 http://dx.doi.org/10.1186/s13063-015-1036-z Text en © Park et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Park, Su Eun
Kim, Ok-Hwan
Kwak, Jung Hyun
Lee, Kwang-Hyoung
Kwon, Young-In
Chung, Kwang Hoe
Lee, Jong Ho
Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial
title Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial
title_full Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial
title_fullStr Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial
title_full_unstemmed Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial
title_short Antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial
title_sort antihyperglycemic effect of short-term arginyl-fructose supplementation in subjects with prediabetes and newly diagnosed type 2 diabetes: randomized, double-blinded, placebo-controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650494/
https://www.ncbi.nlm.nih.gov/pubmed/26578409
http://dx.doi.org/10.1186/s13063-015-1036-z
work_keys_str_mv AT parksueun antihyperglycemiceffectofshorttermarginylfructosesupplementationinsubjectswithprediabetesandnewlydiagnosedtype2diabetesrandomizeddoubleblindedplacebocontrolledtrial
AT kimokhwan antihyperglycemiceffectofshorttermarginylfructosesupplementationinsubjectswithprediabetesandnewlydiagnosedtype2diabetesrandomizeddoubleblindedplacebocontrolledtrial
AT kwakjunghyun antihyperglycemiceffectofshorttermarginylfructosesupplementationinsubjectswithprediabetesandnewlydiagnosedtype2diabetesrandomizeddoubleblindedplacebocontrolledtrial
AT leekwanghyoung antihyperglycemiceffectofshorttermarginylfructosesupplementationinsubjectswithprediabetesandnewlydiagnosedtype2diabetesrandomizeddoubleblindedplacebocontrolledtrial
AT kwonyoungin antihyperglycemiceffectofshorttermarginylfructosesupplementationinsubjectswithprediabetesandnewlydiagnosedtype2diabetesrandomizeddoubleblindedplacebocontrolledtrial
AT chungkwanghoe antihyperglycemiceffectofshorttermarginylfructosesupplementationinsubjectswithprediabetesandnewlydiagnosedtype2diabetesrandomizeddoubleblindedplacebocontrolledtrial
AT leejongho antihyperglycemiceffectofshorttermarginylfructosesupplementationinsubjectswithprediabetesandnewlydiagnosedtype2diabetesrandomizeddoubleblindedplacebocontrolledtrial